DEC 20, 2016 10:49 AM PST

Scripps Florida Scientists Discover New Natural Source of Potent Anti-Cancer Drugs

JUPITER, FL – December 20, 2016 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.

The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.  

The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.

Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.  

The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.

It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.

“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”

“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”

Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.

“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”

In addition to Shen and Yan, first authors of the study, “Strain Prioritization and Genome Mining for Enediyne Natural Products,” include TSRI’s Huiming Ge, Tingting Huang and Hindra. Other authors include Dong Yang, Qihui Teng, Ivana Crnov?i?, Xiuling Li, Jeffrey D. Rudolf, Jeremy R. Lohman and Christoph Rader of TSRI; Yannick Gansemans and Filip Van Nieuwerburgh of Ghent University, Belgium; Yanwen Duan, Xiangcheng Zhu and Yong Huang of Xiangya International Academy of Translational Medicine, Central South University, China; Li-Xing Zhao and Yi Jiang of Yunnan University, China.

The study was supported in part by the Chinese Ministry of Education (111 Project B08034), National High Technology Joint Research Program of China (grant 2011ZX09401-001), National High Technology Research and Development Program of China (grant 2012AA02A705), the National Institutes of Health (grants CA78747 and GM115575), the German Research Foundation and the Arnold and Mabel Beckman Foundation.

This article was originally published on Scripps.edu.

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
NOV 20, 2019
Genetics & Genomics
NOV 20, 2019
Mining 'Junk' DNA for New Cancer Therapeutics
There are vast portions of the genome that don't code for protein, but researchers are learning more about how important they are....
NOV 23, 2019
Cancer
NOV 23, 2019
Can lithium heal damage from radiation?
Research suggests that lithium could play a role in minimizing the negative effects of radiation on the brain. The research was published in Molecular Psyc...
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
DEC 08, 2019
Cancer
DEC 08, 2019
Is there an association between smoking marijuana and cancer?
The controversy with marijuana is only likely to continue as research studies try to understand if marijuana use is associated to an increased risk of canc...
JAN 23, 2020
Cancer
JAN 23, 2020
The role of circular RNA in melanoma
New research published in the journal Cancer Cell investigates the role of circular RNAs in the spread of melanoma. Melanoma is a particularly aggressive c...
FEB 13, 2020
Cancer
FEB 13, 2020
Can Ebola help treat glioblastomas?
You might want to sit down for this. New research published in the Journal of Virology has named a surprising new ally to brain tumors: Ebola. Yes, yo...
Loading Comments...